Sofinnova Venture Partners X L.P. 13D and 13G filings for Vera Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-03-26 7:57 pm Sale |
2024-03-22 | 13D | Vera Therapeutics, Inc. VERA |
Sofinnova Venture Partners X L.P. | 2,813,837 5.400% |
-834,459 (-22.87%) |
Filing |
| 2024-02-20 7:11 pm Purchase |
2024-01-30 | 13D | Vera Therapeutics, Inc. VERA |
Sofinnova Venture Partners X L.P. | 3,648,296 6.900% |
171,215 (+4.92%) |
Filing |
| 2023-02-13 8:43 pm Purchase |
2023-02-06 | 13D | Vera Therapeutics, Inc. VERA |
Sofinnova Venture Partners X L.P. | 3,477,081 8.300% |
285,714 (+8.95%) |
Filing |
| 2023-02-03 7:07 pm Purchase |
2022-03-28 | 13D | Vera Therapeutics, Inc. VERA |
Sofinnova Venture Partners X L.P. | 3,191,367 11.500% |
276,591 (+9.49%) |
Filing |
| 2021-05-24 1:46 pm Purchase |
2021-05-18 | 13D | Vera Therapeutics, Inc. VERA |
Sofinnova Venture Partners X L.P. | 2,914,776 14.500% |
2,914,776 (New Position) |
Filing |